Edwards Lifesciences Community

NYSE:EW Community

1 Narratives written by author
0 Comments on narratives written by author
41 Fair Values set on narratives written by author

Edwards Lifesciences

AN

AnalystConsensusTarget

Consensus Narrative from 30 Analysts

FDA Approvals And Technology Advancements Will Expand Cardiac Care Offerings With TAVR, TMTT, And RESILIA Devices

Key Takeaways TAVR and TMTT technologies drive growth, boosted by expected FDA approval and robust adoption of PASCAL, EVOQUE systems, enhancing future revenue. Strategic acquisitions and RESILIA technology expand portfolio and operational effectiveness, sustaining revenue growth and supporting global market reach.

US$79.50

FV

11.2% undervalued

9.05%

Revenue growth p.a.

0

0

23

7 days ago